This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.

I'm a current customer - what do I need to know about the new 23andMe?

The new 23andMe experience refers to an updated site experience launched in October 2015. Many of our features have been re-designed, combining the functionality of multiple features; some of the underused or outdated features have been discontinued. Learn more about the new experience

We are rolling out access to the new 23andMe gradually. You will receive an email with information about the transition and any actions you need to take in your account when your transition date approaches. All existing customers will be transitioned to the new experience in the upcoming months.

The reports available to you in the new experience depends on your genotyping chip version.

  • Version 4 (v4) will have access to all current Carrier Status*, Wellness, Traits, and Ancestry Reports and Tools in the new experience at no additional cost.
  • Version 3 (v3) announced in 2011 will have access to all current Wellness, Traits, and Ancestry Reports and Tools at no additional cost. Per FDA restrictions, Carrier Status reports cannot be provided to customers genotyped on the v3 chip version. To receive the FDA authorized Carrier Status reports, customers will be able to upgrade to our v4 genotyping chip.
  • Version 2 (v2) announced in 2008 will have access to most of the current Wellness, Traits, and all Ancestry reports and Tools at no additional cost. Per FDA restrictions, Carrier Status reports cannot be provided to customers genotyped on the v2 chip version. To receive the FDA authorized Carrier Status reports, customers will be able to upgrade to our v4 genotyping chip.
  • Version 1 (v1) will have access to most of the current Wellness, Traits, and all Ancestry Reports and Tools at no additional cost. Per FDA restrictions, Carrier Status reports cannot be provided to customers genotyped on the v1 chip version. To receive the FDA authorized Carrier Status reports, customers will be able to upgrade to our v4 genotyping chip.

The Carrier Status category of reports in the new experience meet FDA standards for scientific validity and result accuracy. The regulatory review process we completed with the FDA was specific to the fourth version (v4) of the 23andMe genotyping chip. Per FDA restrictions, these reports cannot be provided to customers genotyped on the any of our previous genotyping chips. While the FDA authorized Carrier Status reports may not be available to you, all existing health-related reports you have opted to receive in your current account will continue to be accessible in the new experience through a Reports Archive link. Learn more about 23andMe and the FDA.

As 23andMe moves forward with seeking FDA authorization to offer new reports, there may be reports that use SNPs not found on previous genotyping chips or new report topics that are only available to customers genotyped on the current, v4 genotyping chip. An upgrade from an older chip to the current chip will be needed to access these reports. Learn more about upgrading chip versions.

 

*Our tests can be used to determine carrier status in adults from saliva collected using an FDA-cleared collection device (Oragene·DX model OGD-500.001), but cannot determine if you have two copies of the genetic variant. Each test is most relevant for people of certain ethnicities. The tests are not intended to diagnose a disease, or tell you anything about your risk for developing a disease in the future. On their own, carrier status tests are not intended to tell you anything about the health of your fetus, or your newborn child's risk of developing a particular disease later in life.


Still have questions? Contact Us

Submit a request

Facebook

Twitter

Phone
1-800-239-5230
Mon - Fri
3am - 5pm PT
Follow
Was this article helpful?
140 out of 227 found this helpful